DCX Systems narrows loss to ₹0.3 Cr on margin recovery; revenue still down 27% YoY
PAT +97.16% YoY · revenue -27.32% · margins expanding
₹140.17 Cr
-27.32% YoY
₹-0.26 Cr
+97.16% YoY
-0.17%
+4.2pp YoY
₹-0.02
DCX Systems' consolidated results for Q2 FY27 (quarter ended September 30, 2026) show a net loss of ₹0.26 Cr, down sharply from a ₹9.04 Cr loss in Q2 FY26 and an ₹8.66 Cr loss in Q1 FY27 — a roughly 97% narrowing on both counts. Consolidated revenue was ₹140.17 Cr, down 27.3% YoY from ₹192.85 Cr, though up 35.9% QoQ off Q1 FY27's execution-delay-hit base of ₹103.13 Cr. On a YoY basis — the primary read — this is a loss that is narrowing rather than a turnaround: the bottom line stayed negative even as the scale of the loss shrank materially against a still-declining topline.
Q2 FY-2027 vs prior quarters
The improvement is margin-led, not volume-led. Net margin recovered to -0.18% from -4.69% a year ago and -8.40% last quarter; EBITDA margin (OPM) improved to -0.85% from -6.65% YoY and -10.36% QoQ. There are no exceptional items in either period, so the move is genuine — cost growth lagged the QoQ revenue recovery, and the other-expense line swung from a ₹3.13 Cr forex loss a year ago to a small forex gain this quarter. Tax expense of ₹2.11 Cr was roughly flat against a near-breakeven pre-tax line (₹1.86 Cr), which is what tipped the group back into a small net loss despite the positive operating trend.
The stock went into the print at ₹146.4, down 3.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Basis matters here: standalone (parent-only) swung to a profit of ₹4.29 Cr (EPS ₹0.39) on revenue of ₹138.23 Cr, while consolidated — the primary basis — posted the ₹0.26 Cr loss (EPS -₹0.02). The ~₹4.55 Cr gap is entirely subsidiary-driven: RASPL and R&D-stage NIART, which the filing notes is still pre-commercial-production and expensing development costs, plus a marginal share of ELTX associate loss. No analyst consensus estimate specific to this quarter turned up in a web search, so vs-street is unknown; management has issued no formal guidance either in our records or via search, so vs-guidance is unknown too — Q1 FY27 brokerage previews had flagged that quarter's revenue as significantly below estimates on execution delays, and this quarter's YoY revenue decline continues that theme in degree even as losses narrow. The quarter's other disclosed developments — ₹18.28 Cr of new orders (Aug 2026) and a Tamil Nadu government JV MoU (Aug 2026) — are both too small or early-stage to have moved this quarter's numbers; the insider-trading window closure (Sept 28) was routine. No management press-release commentary was available to cross-check against the print.
W1
Whether Q3 FY27 revenue sustains the QoQ recovery to ~₹140 Cr or reverts to the execution delays flagged in Q1 FY27 (₹103 Cr)
W2
Whether RASPL/NIART R&D-stage losses (₹4.55 Cr combined this quarter) narrow as NIART's product nears commercial production, per the filing's own note
W3
Whether consolidated PAT crosses into profit, given the loss has narrowed from ₹9.04 Cr (Q2 FY26) to ₹8.66 Cr (Q1 FY27) to ₹0.26 Cr (Q2 FY27)